Shane Atwell

发表

Resource Computationally Designed Bispecific Antibodies using Negative State Repertoires Graphical Abstract Highlights

Andrew Leaver-Fay, Brian Kuhlman, Karen J. Froning, 2016 .

High throughput protein production and crystallization at NYSGXRC.

Stephen K Burley, Kevin Bain, Spencer Emtage, 2008, Methods in molecular biology.

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

Stephen K Burley, Spencer Emtage, Shane Atwell, 2009, Molecular Cancer Therapeutics.

Structures of PHR domains from Mus musculus Phr1 (Mycbp2) explain the loss-of-function mutation (Gly1092-->Glu) of the C. elegans ortholog RPM-1.

Kevin T Bain, Stephen K Burley, Shane Atwell, 2010, Journal of molecular biology.

A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase*

Stephen K Burley, Shane Atwell, S. Burley, 2004, Journal of Biological Chemistry.

Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis

Zhengrong Yang, Shane Atwell, Chi Wang, 2010, Protein science : a publication of the Protein Society.

Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant.

John F Hunt, Diana Wetmore, Spencer Emtage, 2010, Protein engineering, design & selection : PEDS.

Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide‐binding domain 1

Zhengrong Yang, John F Hunt, Diana Wetmore, 2010, Protein science : a publication of the Protein Society.

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface

Andrew Leaver-Fay, Brian Kuhlman, Steven M Lewis, 2014, Nature Biotechnology.

Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure.

Qing Chai, Shane Atwell, S. Atwell, 2016, Molecular pharmaceutics.